Carboxymethylcellulose
ApprovedSmall molecule
AbbVieCarboxymethylcellulose is one of 46 small molecule programs targeting Myopia. It is currently in Approved.
2
Indications
12
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
200 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerPhase 3
Zovirax
BBp Consulting, Inc
Phase 3
Carboxymethylcellulose
AbbVieApproved
Refresh Plus
AbbViePhase 3
Csa
ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
Refresh Optive
AbbViePhase 3
ABBV-444
AbbViePhase 3
Oxervate
DDompé Farmaceutici S.p.A
Phase 3
SYL1001
SSylentis, S.A.
Phase 3
EBI-005
EEleven Biotherapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Eye Disease4 trials
Safety and Efficacy3 trials
Moderate to Severe Dry Eye1 trial
Efficacy and Safety1 trial
2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carboxymethylcellulose. EMBL-EBI & Wellcome Sanger Institute.
- [4]